Dapagliflozin and blood sugar swings in people after weight-loss surgery
Tests dapagliflozin on blood sugar swings in adults after bariatric surgery.
Plain-language title generated from the registry record
Registry title: Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
Key facts
- Where
- Kuwait City, KuwaitSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 21 to 70 who have had bariatric surgery, with or without type 2 diabetes before the surgery. It tests the drug dapagliflozin on blood sugar swings.
- Age
- 21 to 70 years
- Sex
- Women and men can join.
- Disease stage
- People who had bariatric surgery. Some had type 2 diabetes before the surgery and some did not.
- Earlier treatment
- People using insulin or a sulfonylurea cannot join.
- Biomarker or test result
- HbA1c must not be above 10.5.
Main reasons for not taking part
- Type 1 diabetes or secondary diabetes
- History of ketoacidosis, pancreatitis or pancreatectomy
- Reduced kidney function (eGFR below 60 ml/min) or other active diabetes complications
- Pregnant, planning pregnancy or breastfeeding
- Cancer within 5 years of screening
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Source: NCT07515391, who can take part
Where in Kuwait
- Dasman Diabetes InstituteKuwait City, KuwaitNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Dasman Diabetes Institute
- Trial code
- NCT07515391
- Record updated
- 7 April 2026
- Original description
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.Read full original descriptionShow less
Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.
Inclusion: People diagnosed with type 2 diabetes prior to bariatric surgery; People did not have diabetes prior to bariatric surgery; Willing to participate in this study.
Exclusion: Patients using insulin therapy or a sulfonylurea; Type 1 diabetes; Secondary diabetes; History of ketoacidosis; History of pancreatitis and pancreatectomy; Uncontrolled hypertension; Uncontrolled thyroid disease; Any history of serious hypertension reaction to the dapagliflozin or SGLT-2 inhibitor; History of malignancy within 5-year of screening; Presence of any other medical condition that would in the opinion of the investigator, preclude safe participation in the study; History of primary renal glycosuria or hereditary glucose-galactose malabsorption; Active diabetes complications, nephropathy (dipstick positive proteinuria, or reduced eGFR (<60 ml/min), proliferative retinopathy; HbA1c >10.5; Clinically significant abnormal liver function test; Pregnant ladies, or intending pregnancy or breastfeeding; Unable to sign the consent form.